Chimerix, Inc. (CMRX) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (Dec 2024)

FII

11.85%

Held by 35 FIIs

DII

68.36%

Held by 21 DIIs

Promoter

5.67%

How big is Chimerix, Inc.?

22-Jun-2025

As of Apr 22, Chimerix, Inc. has a market capitalization of 768.05 million, with net sales of 0.22 million and a net profit of -88.38 million over the last four quarters. The balance sheet as of Dec'24 shows shareholder's funds of 121.68 million and total assets of 146.01 million.

What does Chimerix, Inc. do?

22-Jun-2025

Chimerix, Inc. is a biotechnology company focused on developing medicines for unmet medical needs. As of December 2024, it has a market cap of $768.05 million, with net sales of $0 and a net loss of $23 million.

Who are in the management team of Chimerix, Inc.?

22-Jun-2025

As of March 2022, the management team of Chimerix, Inc. includes Independent Chairman Ms. Martha Demski, President and CEO Mr. Michael Sherman, and several Independent Directors: Dr. Catherine Gilliss, Mr. Edward Greissing, Mr. Patrick Machado, Dr. Robert Meyer, and Mr. Fred Middleton. They are responsible for the company's strategic direction and governance.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals: Major

Market cap

USD 768 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

98.61%

Debt Equity

-1.08

Return on Equity

-72.64%

Price to Book

6.31

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Dec 2024)

Net Profit:

-23 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

140.56%

6 Months

879.02%

1 Year

844.69%

2 Years

588.71%

3 Years

78.29%

4 Years

4.4%

5 Years

437.11%

Chimerix, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-55.85%

EBIT Growth (5y)

-167.01%

EBIT to Interest (avg)

-77.01

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.08

Sales to Capital Employed (avg)

0.06

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

72.15%

ROCE (avg)

ROE (avg)

13.41%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.31

EV to EBIT

-6.60

EV to EBITDA

-6.60

EV to Capital Employed

-68.92

EV to Sales

637.13

PEG Ratio

Dividend Yield

98.61%

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-72.64%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 30 Schemes (14.12%)

Foreign Institutions

Held by 35 Foreign Institutions (11.85%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2024 is -26.37% vs 13.33% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-24.50",
          "val2": "-20.80",
          "chgp": "-17.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-23.00",
          "val2": "-18.20",
          "chgp": "-26.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-430,736.80%",
          "val2": "-5,202,500.00%",
          "chgp": "4,77,176.32%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -33.33% vs -99.11% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -7.67% vs -147.68% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.30",
          "chgp": "-33.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-96.60",
          "val2": "-93.10",
          "chgp": "-3.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-88.40",
          "val2": "-82.10",
          "chgp": "-7.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-455,504.70%",
          "val2": "-287,237.70%",
          "chgp": "-16,826.70%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'24 - YoY

Dec'24

Dec'23

Change(%)

Net Sales

0.10

0.00

Operating Profit (PBDIT) excl Other Income

-24.50

-20.80

-17.79%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-23.00

-18.20

-26.37%

Operating Profit Margin (Excl OI)

-430,736.80%

-5,202,500.00%

4,77,176.32%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Consolidated Net Profit

YoY Growth in quarter ended Dec 2024 is -26.37% vs 13.33% in Dec 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.20

0.30

-33.33%

Operating Profit (PBDIT) excl Other Income

-96.60

-93.10

-3.76%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-88.40

-82.10

-7.67%

Operating Profit Margin (Excl OI)

-455,504.70%

-287,237.70%

-16,826.70%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -33.33% vs -99.11% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -7.67% vs -147.68% in Dec 2023

All Annual Results

Company CV

About Chimerix, Inc.

Chimerix, Inc.

Pharmaceuticals: Major

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. The Company has two clinical-stage product candidates, dociparstat sodium (DSTAT) and brincidofovir (BCV). DSTAT is a heparin derivative that enables dosing at higher concentrations to achieve anti-inflammatory. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia (AML) and as a potential treatment for acute lung injury (ALI) in Coronavirus disease 2019 (COVID-19) patients. BCV is an investigational lipid conjugate that is in development as a medical countermeasure for smallpox. The Company’s other pipeline candidates include ONC201, ONC206, ONC206 and ONC212.

Company Coordinates

Company Details

2505 Meridian Pkwy Ste 100 , DURHAM NC : 27713-2288

Tel: 1 919 8061074

http://www.chimerix.com/

Registrar Details

Chimerix, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Chimerix, Inc.?

Watch in Real-Time

What does Chimerix, Inc. do?

Who are in the management team of Chimerix, Inc.?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Dec'24 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Chimerix, Inc.

Company Coordinates